Advertisement

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

  • Lihteh Wu
  • María A. Martínez-Castellanos
  • Hugo Quiroz-Mercado
  • J. Fernando Arevalo
  • María H. Berrocal
  • Michel E. Farah
  • Mauricio Maia
  • José A. Roca
  • Francisco J. Rodriguez
  • for the Pan American Collaborative Retina Group (PACORES)
Retinal Disorders

Abstract

Background

Vascular endothelial growth factor (VEGF) plays an important role in many diseases of the posterior pole that are characterized by macular edema and/or intraocular neovascularization. Recently anti-VEGF agents such as ranibizumab and pegaptanib sodium have been shown to be beneficial in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). However in most parts of the world, both pegaptanib sodium and ranibizumab are not readily available. Bevacizumab, a humanized recombinant monoclonal IgG antibody that binds and inhibits all VEGF isoforms, has been proposed as an alternative treatment option.

Methods

A total of 1,265 consecutive patients were injected with bevacizumab for diseases such as proliferative diabetic retinopathy, diabetic macular edema, retinal vein occlusions, and CNV of several etiologies including ARMD at eight Latin American institutions from 1 September 2005 to 31 January 2006. Of these 1,265, 92 were excluded because they were injected once and lost to follow-up. The remaining 1,173 patients constitute the subjects of this retrospective, multicenter, open label, uncontrolled interventional case series that reports the cumulative systemic and ocular adverse events following intravitreal bevacizumab during 12 months of follow-up. Patients were examined at baseline and then monthly. If the patients were unable to attend the 12-month visit, a telephone interview was conducted to assess for possible systemic complications.

Results

A total of 4,303 intravitreal injections of bevacizumab on 1,310 eyes was reported. All 1,173 patients were accounted for at the 12-month visit. Systemic adverse events were reported in 18 (1.5%) patients. These included seven (0.59%) cases of an acute elevation of systemic blood pressure, six (0.5%) cerebrovascular accidents, five (0.4%) myocardial infarctions, two (0.17%) iliac artery aneurysms, two (0.17%) toe amputations and five (0.4%) deaths. Ocular complications included seven (0.16%) bacterial endophthalmitis, seven (0.16%) tractional retinal detachments, four (0.09%) uveitis, and a case (0.02%) each of rhegmatogenous retinal detachment and vitreous hemorrhage.

Conclusion

Despite the limited follow-up, repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year.

Keywords

Age-related macular degeneration Angiogenesis Choroidal neovascularization Diabetic macular edema Intravitreal bevacizumab Proliferative diabetic retinopathy Safety 

References

  1. 1.
    Adamis AP, Aiello LP, D’Amato RA (1999) Angiogenesis and ophthalmic disease. Angiogenesis 3:9–14PubMedCrossRefGoogle Scholar
  2. 2.
    Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111–118PubMedCrossRefGoogle Scholar
  3. 3.
    Qaum T, Xu Q, Joussen AM, et al (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408–2413PubMedGoogle Scholar
  4. 4.
    Saishin Y, Saishin Y, Takahashi K, et al (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241–248PubMedCrossRefGoogle Scholar
  5. 5.
    Cunningham ET Jr, Adamis AP, Altaweel M, et al (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747–1757PubMedCrossRefGoogle Scholar
  6. 6.
    Gragoudas ES, Adamis AP, Cunningham ET Jr, et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816PubMedCrossRefGoogle Scholar
  7. 7.
    Heier JS, Antoszyk AN, Pavan PR, et al (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113(642):e1–e4Google Scholar
  8. 8.
    Hurwitz H, Fehrenbacher L, Novotny W, et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  9. 9.
    Michels S, Rosenfeld PJ, Puliafito CA, et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339PubMedGoogle Scholar
  11. 11.
    Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335PubMedGoogle Scholar
  12. 12.
    Aiello LP, Brucker AJ, Chang S, et al (2004) Evolving guidelines for intravitreous injections. Retina 24:S3–19PubMedCrossRefGoogle Scholar
  13. 13.
    Drolet DW, Nelson J, Tucker CE, et al (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17:1503–1510PubMedCrossRefGoogle Scholar
  14. 14.
    Gaudreault J, Fei D, Rusit J, et al (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726–733PubMedCrossRefGoogle Scholar
  15. 15.
    van Wijngaarden P, Coster DJ, Williams KA (2005) Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293:1509–1513PubMedCrossRefGoogle Scholar
  16. 16.
    Sane DC, Anton L, Brosnihan KB (2004) Angiogenic growth factors and hypertension. Angiogenesis 7:193–201PubMedCrossRefGoogle Scholar
  17. 17.
    Kernt M, Neubauer AS, Kampik A (2007) Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85:119–120PubMedCrossRefGoogle Scholar
  18. 18.
    Ratner M (2004) Genentech discloses safety concerns over Avastin. Nat Biotechnol 22:1198PubMedCrossRefGoogle Scholar
  19. 19.
    Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344–1349PubMedCrossRefGoogle Scholar
  20. 20.
    Spaide RF, Laud K, Fine HF, et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390PubMedCrossRefGoogle Scholar
  21. 21.
    Avery RL, Pieramici DJ, Rabena MD, et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3):363–372 e5PubMedCrossRefGoogle Scholar
  22. 22.
    (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198–207Google Scholar
  23. 23.
    (2001)Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560Google Scholar
  24. 24.
    Slakter JS, Bochow TW, D’Amico DJ, et al (2006)Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 11:3–13CrossRefGoogle Scholar
  25. 25.
    Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19:361–372PubMedGoogle Scholar
  26. 26.
    Geiss LS, Herman WH, PJS (2007) Mortality in Non-Insulin Dependent Diabetes. Diabetes in America, 2nd Ed. http://diabetes.niddk.nih.gov/dm/pubs/america/pdf/chapter11.pdf. Accessed February 14
  27. 27.
    Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257–261PubMedCrossRefGoogle Scholar
  28. 28.
    Shahar J, Avery RL, Heilweil G, et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262–269PubMedCrossRefGoogle Scholar
  29. 29.
    Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26:270–274PubMedCrossRefGoogle Scholar
  30. 30.
    Luthra S, Narayanan R, Marques LE, et al (2006) Evaluation of in vitro effects of bevacizumab (avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26:512–518PubMedCrossRefGoogle Scholar
  31. 31.
    Luke M, Warga M, Ziemssen F, et al (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90:1178–1182PubMedCrossRefGoogle Scholar
  32. 32.
    Jager RD, Aiello LP, Patel SC, Cunningham ET Jr (2004) Risks of intravitreous injection: a comprehensive review. Retina 24:676–698PubMedCrossRefGoogle Scholar
  33. 33.
    Ziemssen F, Warga M, Neuhann IM, et al (2006) Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function? Br J Ophthalmol 90:922PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Lihteh Wu
    • 1
    • 8
  • María A. Martínez-Castellanos
    • 2
  • Hugo Quiroz-Mercado
    • 2
  • J. Fernando Arevalo
    • 3
  • María H. Berrocal
    • 4
  • Michel E. Farah
    • 5
  • Mauricio Maia
    • 5
  • José A. Roca
    • 6
  • Francisco J. Rodriguez
    • 7
  • for the Pan American Collaborative Retina Group (PACORES)
  1. 1.Instituto de Cirugía OcularSan JoséCosta Rica
  2. 2.Asociación Para Evitar La CegueraMexicoMexico
  3. 3.Clínica Oftalmológica Caracas CentroCaracasVenezuela
  4. 4.University of Puerto RicoSanturcePuerto Rico
  5. 5.Vision InstituteFederal University of Sao PauloSao PauloBrazil
  6. 6.Clínica Ricardo PalmaLimaPeru
  7. 7.Fundación Oftalmológica NacionalBogotáColombia
  8. 8.San JoséCosta Rica

Personalised recommendations